HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term ResultsMariantonietta Colozza, Maurizio Tonato, Giancarlo Bisagni et al.|Clinical Breast Cancer|2005Cited by 19
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised studyMariantonietta Colozza, Maurizio Tonato, Giancarlo Bisagni et al.|European Journal of Cancer|2002Cited by 14